Association of Irisin with the Oxidant-Antioxidant Parameters in Type 2 Diabetic Patients According to Age in Thi-Qar Province, Iraq

Saad H Al-Badry

Biology Department, College of Science, University of Thi-Qar, Iraq

Khalid G Al-Fartoosi

Biology Department, College of Science, University of Thi-Qar, Iraq

Download PDF

http://doi.org/10.37648/ijrst.v10i01.002

Abstract

References

1. Allian, C.C.; Poon, L.S.; Chan, C.S.; Richmond, W. and FU, P.C. (1974) “Enzymatic Determination of Total Serum Cholesterol.” Clinical Chem. 20, (4): 470–75.
2. Arias-Loste, M. T., Ranchal, I., Romero-Gómez, M., and Crespo, J. (2014). Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. International journal of molecular sciences, 15(12), 23163-23178.‏
3. Assyov Y., Gateva A., Tsakova A., Kamenov Z. (2016).Irisin in glucose continuum. Exp. Clin. Endocrinol. Diabetes; 124: 22–27.
4. Badimon, J. J., Badimon, L., & Fuster, V. (1990). Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. The Journal of clinical investigation, 85(4), 1234-1241.
5. Bains, S., Anyaeche, C., Wyatt, A., Coker, O., & Bolodeoku, J. (2017). Evaluation of Point of Care Test (POCT), i-CHROMA™ Serum C-Reactive Protein (CRP) Assay and Microalbumin Urine (MAU) Methods. Annals of Clinical and Laboratory Research, 5(3), 192.
6. Bajaj, S., and Khan, A. (2012). Antioxidants and diabetes. Indian journal of endocrinology and metabolism, 16(Suppl 2), S267.‏
7. Bashan, N.; Kovsan, J.; Kachko, I.; Ovadia, H.; and Rudich, A. (2009). Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiological Reviews, 89(1), 27-71.‏
8. Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., and Kajimura, S. (2012). A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481(7382), 463-8.
9. Choi, Y. K., Kim, M. K., Bae, K. H., Seo, H. A., Jeong, J. Y., Lee, W. K., and Park, K. G. (2013). Serum irisin levels in new-onset type 2diabetes. Diabetes research and clinical practice, 100(1), 96-101.
10. De Feo, P.; Volpi, E.; Lucidi, P.; Cruciani, G.; Reboldi, G.; Siepi, D., and Bolli, G. B. (1993). Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes, 42(7), 995-1002
11. Ebert, T., Focke, D., Petroff, D., Wurst, U., Richter, J., Bachmann, A., and Bast, I. (2014). Serum levels of the myokine irisin in relation to metabolic and renal function. European journal of endocrinology, 170(4), 501-506.
12. Endocrinologica, M. (2017). Irisin as a regulator of bone and glucose metabolism: a narrative review. Minerva endocrinologica.
13. Espes, D., Lau, J., and Carlsson, P. O. (2015). Increased levels of irisin in people with long‐standing Type 1 diabetes. Diabetic medicine, 32(9), 1172-1176.
14. Fong, K. L.; McCay, P. B.; Poyer, J. L.; Keele, B. B., and Misra, H. (1973). Evidence that peroxidation of lysosomal membranes is initiated by hydroxyl free radicals produced during flavin enzyme activity. Journal of Biological Chemistry, 248(22), 7792-7797.‏
15. Forouhi, N. G., & Wareham, N. J. (2014). Epidemiology of diabetes. Medicine (Abingdon). 42 (12): 698–702.
16. Fukushima, Y., Kurose, S., Shinno, H., Cao Thi Thu, H., Tamanoi, A., Tsutsumi, H., and Kimura, Y. (2016). Relationships between serum irisin levels and metabolic parameters in Japanese patients with obesity. Obesity science & practice, 2(2), 203-209.
17. Goldstein, J. L., Ho, Y. K., Basu, S. K., & Brown, M. S. (1979). Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proceedings of the National Academy of Sciences, 76(1), 333-337.
18. Harris, M. I. (1998). Diabetes in America: epidemiology and scope of the problem. Diabetes care, 21(Supplement 3), C11-C14.
19. Hope, S. V., Knight, B. A., Shields, B. M., Strain, W. D., Hattersley, A. T., Choudhary, P., and Jones, A. G. (2016). Low c-peptide is associated with high glycemic variability and hypoglycemia in insulin-treated patients with type 2 diabetes. Diabet Med, 33, 144.
20. Jeppsson, J. O., Kobold, U., Barr, J., Finke, A., Hoelzel, W., Hoshino, T., ... & Thienpont, L. (2002). Approved IFCC reference method for the measurement of HbA1c in human blood. Clinical chemistry and laboratory medicine, 40(1), 78-89.
21. Jones, A. G., and Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803-817.‏
22. Kamran M. A. (2010). Association between high risk foot, retinopathy and hba1c in Saudi diabetic population. Pak J Physiol., 622-28.
23. Kramer, C. K., Choi, H., Zinman, B., and Retnakaran, R. (2014). Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function. Diabetes Care, DC_132591.‏
24. Kuhtreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold III, P., Burger, D and Faustman, D. L. (2015). Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabetic Medicine, 32(10), 1346-1353.‏
25. Lachin, J. M., McGee, P., Palmer, J. P., and DCCT/EDIC research group. (2014). Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes, 63(2), 739-748.
26. Lee, H. J.; Lee, J. O.; Kim, N.; Kim, J. K.; Kim, H. I.; Lee, Y. W., and Hwang, S. (2015). Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK. Molecular Endocrinology, 29(6), 873-881.‏
27. Leighton, E., Sainsbury, C. A., and Jones, G. C. (2017). A practical review of C-peptide testing in diabetes. Diabetes therapy, 8(3), 475-487.‏
28. Liu, J. J., Wong, M. D., Toy, W. C., Tan, C. S., Liu, S., Ng, X. W., .and Lim, S. C. (2013). Lower circulating irisin is associated with type 2 diabetes mellitus. Journal of Diabetes and its Complications, 27(4), 365-369.‏
29. McMillan, D. E. (1989). Increased levels of acute-phase serum proteins in diabetes. Metabolism, 38(11), 1042-1046.‏
30. Menden, E. E.; Boiano, J. M.; Murthy, L., and Petering, H. G. (1977). Modification of a P-Phenylenediamine Oxidase Method to Permit Non-Automated Ceruloplasmin Determinations in Batches of Rat Serum or Plasma Microsamples. Analytical Letters, 10(3), 197-204.‏
31. Miyazawa, H., Bannai, H., Yanase, T., Morita, C., Satoh, S., Sugiyama, J., ... & Inouye, S. (1999). A reverse-sandwich enzyme-linked immunosorbent assay for verocytotoxin 1 and 2 antibodies in human and bovine sera. Clin. Diagn. Lab. Immunol., 6(5), 701-704.
32. Moreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G., Tinahones, F., and Fernández-Real, J. M. (2013). Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. The Journal of Clinical Endocrinology & Metabolism, 98(4), E769-E778.
33. Morgantini, C.; Natali, A.; Boldrini, B.; Imaizumi, S.; Navab, M.; Fogelman, A. M., and Reddy, S. T. (2011). Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes, DB_110378.‏
34. Nuttall, F. Q. (2015). Body mass index: obesity, BMI, and health: a critical review. Nutrition today, 50(3), 11.
35. Peter O. and Kwiterovich, Jr., M.D. (2004). Diagnostics, R., & Diagnostics, B. M. Laboratory Procedure Manual. Laboratory Procedure Manual, 410-614-1030.
36. Rolo, A. P., and Palmeira, C. M. (2006). Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology, 212(2), 167-178.‏
37. Rustemeijer, C .; Schouten, J. A .; Janssen, E. N .; Spooren, P. F . and Van Doormaal, J. J. (1997). Pravastatin in diabetes associated hypercholesterolemia. Acta. diabetol., 34(4): 294-300.
38. Ryu, T. Y.; Park, J., and Scherer, P. E. (2014). Hyperglycemia as a risk factor for cancer progression. Diabetes & Metabolism Journal, 38(5), 330-336.‏
39. Sanchis-Gomar, F., & Perez-Quilis, C. (2014). The p38–PGC-1α–irisin–betatrophin axis: Exploring new pathways in insulin resistance. Adipocyte, 3(1), 67-68.‏
40. Sanchis-Gomar, F., Lippi, G., Mayero, S., Perez‐Quilis, C., & García‐Giménez, J. L. (2012). Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. Journal of diabetes, 4(3), 196-196.
41. Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016). Diabetes dyslipidemia. Diabetes Therapy, 7(2), 203-219.
42. Trinder, P. (1969). Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Annals of clinical Biochemistry, 6(1), 24-27.
43. Vaziri, N. D.; Sato, T. and Liang, K.(2003). Molecular mechanism of expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. hypercholesterolemia. Acta. diabetol., 34(4): 294-300.
44. World Health Organization. (2016). World health statistics 2016: monitoring health for the SDGs sustainable development goals. World Health. Organization.
45. Xiong, X. Q., Chen, D., Sun, H. J., Ding, L., Wang, J. J., Chen, Q., and Gao, X. Y. (2015). FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1852(9), 1867-1875.
46. Yan, B.; Shi, X.; Zhang, H.; Pan, L. and Ma, Z. et al. (2014). Association of Serum Irisin with Metabolic Syndrome in Obese Chinese Adults. PLoS ONE., 9(4).
47. Zhang, C., Ding, Z., Lv, G., Li, J., Zhou, P., & Zhang, J. (2016). Lower irisin level in patients with type 2 diabetes mellitus: A case‐control study and meta-analysis meta. Journal of diabetes, 8(1), 56-62.‏
48. Zhang, M., Chen, P., Chen, S., Sun, Q., Zeng, Q. C., Chen, J. Y., and Wang, J. K. (2014). The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci, 18(11), 1567-72.‏

Back